Clinical Trials Directory

Trials / Completed

CompletedNCT02806414

Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.

A Single Site Evaluation of the Inhibitory Effects of Topical Ivermectin on Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation and on the Skin Microbiome in Rosacea.

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
25 (actual)
Sponsor
University of California, San Diego · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study will assess the role of topical Ivermectin 1% cream and its effect on protease and antimicrobial peptide expression and on the skin microbiome (the microorganisms that live on the skin) in rosacea. This is a single-site 16-week open-label study at University of California, San Diego. The investigators will do this by first measuring serine protease activity and cathelicidin and skin microbiome of all subjects. All subjects will receive Ivermectin topical cream and will be instructed on how to apply it daily for 12 weeks. Participants will return for monthly visits during which their clinical symptoms of facial redness and number of facial papules will be scored, and they will have repeat tape stripping and/or skin swabs. At the end of the study, tape strips and skin swabs will be analyzed to determine serine protease activity and skin microbiome of participants at each of their visits and expression of cathelicidin (LL-37) mRNA. The investigators will then look at changes in serine protease activity and LL-37 expression and skin microbiome over time, and they will also determine whether or not these changes correlate with disease severity.

Conditions

Interventions

TypeNameDescription
DRUGIvermectin

Timeline

Start date
2016-07-01
Primary completion
2019-07-01
Completion
2021-05-01
First posted
2016-06-20
Last updated
2021-10-05
Results posted
2020-07-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02806414. Inclusion in this directory is not an endorsement.